scholarly journals Immune Response and Intestinal Permeability in Children With Acute Gastroenteritis Treated With Lactobacillus rhamnosus GG: A Randomized, Double-Blind, Placebo-Controlled Trial

2014 ◽  
Vol 58 (8) ◽  
pp. 1107-1115 ◽  
Author(s):  
Kulandaipalayam N. C. Sindhu ◽  
Thuppal V. Sowmyanarayanan ◽  
Anu Paul ◽  
Sudhir Babji ◽  
Sitara S. R. Ajjampur ◽  
...  
Keyword(s):  
Immune Response ◽  
Intestinal Permeability ◽  
Acute Gastroenteritis ◽  
Controlled Trial ◽  
Lactobacillus Rhamnosus ◽  
Lactobacillus Rhamnosus Gg ◽  
Double Blind ◽  
Double Blind Placebo

Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial

Vaccine ◽  
1994 ◽  
Vol 12 (13) ◽  
pp. 1185-1189 ◽  
Author(s):  
Th.M.E. Govaert ◽  
M.J.W. Sprenger ◽  
G.J. Dinant ◽  
K. Aretz ◽  
N. Masurel ◽  
...  
Keyword(s):  
Immune Response ◽  
Influenza Vaccination ◽  
Elderly People ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Randomised controlled trial ofLactobacillus rhamnosus(LGG) versus placebo in children presenting to the emergency department with acute gastroenteritis: the PECARN probiotic study protocol

BMJ Open ◽  
2017 ◽  
Vol 7 (9) ◽  
pp. e018115 ◽  
Author(s):  
David Schnadower ◽  
Phillip I Tarr ◽  
T Charles Casper ◽  
Marc H Gorelick ◽  
Michael J Dean ◽  
...  
Keyword(s):  
Acute Gastroenteritis ◽  
Statistical Power ◽  
Controlled Trial ◽  
Severe Disease ◽  
Lactobacillus Rhamnosus ◽  
Research Network ◽  
Controlled Study ◽  
Double Blind ◽  
Data Set ◽  
Public Data

IntroductionAcute gastroenteritis (AGE) is a common and burdensome condition that affects millions of children worldwide each year. Currently available strategies are limited to symptomatic management, treatment and prevention of dehydration and infection control; no disease-modifying interventions exist. Probiotics, defined as live microorganisms beneficial to the host, have shown promise in improving AGE outcomes, but existing studies have sufficient limitations such that the use of probiotics cannot currently be recommended with confidence. Here we present the methods of a large, rigorous, randomised, double-blind placebo-controlled study to assess the effectiveness and side effect profile ofLactobacillus rhamnosusGG (LGG) (ATCC 53103) in children with AGE.Methods and analysisThe study is being conducted in 10 US paediatric emergency departments (EDs) within the federally funded Pediatric Emergency Care Applied Research Network, in accordance with current SPIRIT and CONSORT statement recommendations. We will randomise 970 children presenting to participating EDs with AGE to either 5 days of treatment with LGG (1010colony-forming unit twice a day) or placebo between July 2014 to December 2017. The main outcome is the occurrence of moderate-to-severe disease over time, as defined by the Modified Vesikari Scale. We also record adverse events and side effects related to the intervention. We will conduct intention-to-treat analyses and use an enrichment design to restore the statistical power in case the presence of a subpopulation with a substantially low treatment effect is identified.Ethics and disseminationInstitutional review board approval has been obtained at all sites, and data and material use agreements have been established between the participating sites. The results of the trial will be published in peer-reviewed journals. A deidentified public data set will be made available after the completion of all study procedures.Trial registration numberNCT01773967.

Lactobacillus rhamnosus GG in the middle ear after randomized, double-blind, placebo-controlled oral administration

2014 ◽  
Vol 78 (10) ◽  
pp. 1637-1641 ◽  
Author(s):  
Laura Tapiovaara ◽  
Liisa Lehtoranta ◽  
Elisa Swanljung ◽  
Harri Mäkivuokko ◽  
Sanna Laakso ◽  
...  
Keyword(s):  
Oral Administration ◽  
Middle Ear ◽  
Lactobacillus Rhamnosus ◽  
Lactobacillus Rhamnosus Gg ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document